Purpose of Review: to describe and compare the efficacy and safety of the main PTH treatments, namely PTH(1–84) and palopegteriparatide, for the management of hypoparathyroidism. Recent Findings: neither PTH (1–84) nor PTH(1–34) have been shown a clear and consistent favorable impact on the 24 h urinary calcium excretion normalization, while the positive effect on quality of life is still debated. Recently, the Food & Drug Administration and the European Medicines Agency approved palopegteriparatide as the first true replacement therapy for hypoPT management. Palopegteriparatide is a prodrug of PTH(1–34), administered once daily, and designed to provide continuous exposure to released PTH over a 24-h dosing period. According to phase II and phase III studies, palopegteriparatide seems to fill the gaps identified in existing therapies for hypoPT. Summary: Palopegteriparatide is the first real replacement therapy for the management of hypoparathyroidism and seems to fill the gaps identified in existing therapies for hypoPT.
Palermo, A., Naciu, A.M., Donovan, Y.K.T., Tabacco, G., Zavatta, G. (2025). PTH Substitution Therapy for Chronic Hypoparathyroidism: PTH 1–84 and Palopegteriparatide. CURRENT OSTEOPOROSIS REPORTS, 23(1), 1-10 [10.1007/s11914-025-00905-6].
PTH Substitution Therapy for Chronic Hypoparathyroidism: PTH 1–84 and Palopegteriparatide
Zavatta G.
2025
Abstract
Purpose of Review: to describe and compare the efficacy and safety of the main PTH treatments, namely PTH(1–84) and palopegteriparatide, for the management of hypoparathyroidism. Recent Findings: neither PTH (1–84) nor PTH(1–34) have been shown a clear and consistent favorable impact on the 24 h urinary calcium excretion normalization, while the positive effect on quality of life is still debated. Recently, the Food & Drug Administration and the European Medicines Agency approved palopegteriparatide as the first true replacement therapy for hypoPT management. Palopegteriparatide is a prodrug of PTH(1–34), administered once daily, and designed to provide continuous exposure to released PTH over a 24-h dosing period. According to phase II and phase III studies, palopegteriparatide seems to fill the gaps identified in existing therapies for hypoPT. Summary: Palopegteriparatide is the first real replacement therapy for the management of hypoparathyroidism and seems to fill the gaps identified in existing therapies for hypoPT.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
